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Posttransplant lymphoproliferative disorder (PTLD) is a serious complication following solid organ transplantation with an
annual incidence rate of 3–5% in lung-transplant recipients. Pathogenesis indicates a strong association with functional over-
immunosuppression and EBV infection. Clinical improvement is generally observed with reduction in immunosuppression
intensity alone. We present a case of a 24-year-old woman with EBV-associated PTLD following lung transplant where decreasing
the immunosuppressionimproved PTLD but wasineﬀective againstcontrollingthe EBV infection. Foscarnetin combinationwith
immunoglobulins was successfully administered to cause a remission of the EBV infection. This is the second case reported of
a persistent EBV infection after reducing immunosuppression levels and evidence of PTLD remission that required foscarnet for
EBV infection control.
1.Introduction
Althoughtheexactpathogenesisisuncertain,itisknownthat
functional over-immunosuppression and Epstein-Barr virus
(EBV) infections are strong risk factors for the development
of PTLD. Lung-transplant recipients have at least a twofold
greater risk of developing PTLD compared to other solid-
organ transplants. The general therapy for PTLD includes
therestorationofcellularimmunitybyreducingtheintensity
of immunosuppression. Conventional antiviral therapy with
acyclovir, valganciclovir, or ganciclovir has proven ineﬀec-
tive, but yet remains the recommended ﬁrst-line therapy for
EBVinfection in casesofPTLD [1]. Herein, we present a case
of EBV-associated PTLD following lung transplantation
showing clinical improvement of lymphadenopathy with
reduction in immunosuppression intensity but having per-
sistent EBV infection, requiring foscarnet for viral clearance.
2.Case Report
A 24-year-old woman underwent successful sequential bilat-
eral living lobar lung transplantation for cystic ﬁbrosis. EBV
serology was positive for both donor and recipient. Stan-
dard triple-drug immunosuppressive medications included
tacrolimus, prednisone, and mycophenolate mofetil. Four
years following transplant, she experienced her ﬁrst and only
mild acute cellular rejection (ISHLT grade A2) that was suc-
cessfully treated with a 3-day course of intravenous solume-
drol (1000mg) followed by prednisone taper. Her immuno-
suppressive regimen at the time included prednisone 5mg
daily, tacrolimus 2.5mg twice daily with a therapeutic drug
levelof12.4ng/mL,andmycophenolatemofetil250mgtwice
daily. Additionally, she developed chronic kidney disease
with a GFR 40cc/min/1.73m2.T op r e s e r v er e n a lf u n c t i o n ,
sirolimus was added for calcineurin-inhibitor-minimization2 Journal of Transplantation
Figure 1: CT scan of chest demonstrated multicompartmental
mediastinal lymphadenopathy, for example, a right paratracheal
node measuring 14mm in short axis.
immunosuppressive regimen. Additionally,one unitofCMV
negative/leucophoresed blood was transfused for a moderate
degree of normocytic/normochromic anemia (Hct 22%).
The workup for blood loss had been inconclusive, and no
further events occurred when seen in subsequent visits in
clinic.
S i xm o n t h sl a t e r ,s h ew a sa d m i t t e df o rf a t i g u ea n d
“B symptoms” of fevers, night sweats, and chills of three
days duration. All other reviews of systems were negative.
Aside from tachycardia at 110beats/minute and febrile
at 39.4C, other vitals were normal. Physical examination
was only remarkable for a palpable 2cm × 2cm right-
sided ﬁrm and nonpainful cervical lymph node. Com-
plete blood count showed pancytopenia, leucocyte count
2.4 × 103 cells/mL with an absolute neutrophil count
1.6 × 103 cells/mL, hematocrit 28.7%, and platelets 104 ×
103 cells/mL. The immunosuppression regimen included
prednisone 10mg daily, tacrolimus 0.5mg twice daily, my-
cophenolate mofetil 500mg twice daily, and rapamycin 2mg
daily. Tacrolimus and rapamycin levels were 11.4ng/dL and
12.4ng/dL, respectively. Empiric antibiotics were admin-
istered for potential sepsis. All ﬁnal bacterial, fungal,
and mycobacterial culture isolates were negative. Poly-
m e r a s ec h a i nr e a c t i o n( P C R )d i dn o tr e v e a lC M V - D N A ,
but did demonstrate a signiﬁcant number of EBV-DNA
genome copies (870,908DNAcopies/mL blood). A com-
bined approach of intravenous ganciclovir 5mg/kg twice
daily with immunoglobulin (CMV IG) administration and
rapid reductionof baseline immunosuppression therapy was
instituted. Both prednisone and sirolimus were tapered to
5mg daily and 1mg every 72 hours, respectively, giving
a therapeuticdrug levelof sirolimus at 6.9ng/dL. Tacrolimus
and mycophenolate mofetil were completely withdrawn. CT
of chest, abdomen, and pelvis revealed numerous lymph
nodes in the mediastinum, cervical, and abdominal regions
(Figure 1). Excisional lymph node biopsy of the right
scalene lymph node was positive for polymorphic PTLD
(Figure 2). The immunohistochemistry disclosed positive
lymphocytes for CD-20, EBER, and EBV-LMP-1. Bone
marrow biopsy was devoid of lymphoma. Intravenous
ganciclovir was initiated for the control of the EBV. With
the reduction in immunosuppression therapy, a desired
eﬀect of lymph node size reduction was seen on CT scan
22 days later (Figure 3). However, while on intravenous
ganciclovir, PCR analysis detected continued elevation in
EBV DNA levels for an additional 35 days. The peak value
was 10,200,000DNAcopies/mL. Ganciclovir was changed to
foscarnet 90mg/kg. This prompted a signiﬁcant reduction
in EBV PCR values to undetectable levels as depicted in
Figure 4. Aside from a mild increase in serum creatinine, no
other adverse events occurred. During the next 9 months,
all the radiographic and serologic investigations conﬁrmed
complete remission.
3.Discussion
PTLD is a well-recognized complication of solid organ
and hematopoietic stem cell transplantation. It is a part
of a group of heterogenous lymphoproliferative disorders
primarily related to the oncogenic epstein-barr virus (EBV).
The incidence rate of PTLD in lung transplantation is
between 3–5% [2]. It generally develops within a year of
transplantation but in our patient it developed 5 years after
lung transplant. Overall mortality rates have been reported
between 60 and 100%. Cytotoxic T-cell response is pivotal
in controlling the reactivation and proliferation of the virus.
EBV-infected CD20+ B cells replicate and proliferate in
an environment of T-cell over-immunosuppression. Rather
than undergoing lytic replication, EBV-infected cells within
PTLD lesions replicate through proliferation of the trans-
formed B cells. A constant degree of excessive immunosup-
pression allows forproliferation ofPTLD B-cell lymphocytes
to manifest in an aggressive monoclonal or polyclonal B-cell
lymphoma [3].
Besides impaired T-cell immunity, other risk factors
of developing EBV infection following lung transplant
include donor or recipient EBV seropositivity, a natural
primary transmission, and HLA-A3 expression. The highest
risk groups are patients with EBV seroreactive mismatch
(D+/R−). This group has a 30-fold higher risk compared
to the seronegative group (D−/R−). Molecular analysis,
however, shows that EBV-associated PTLD following lung
transplant more commonly originates from the recipient
[4]. There is currently debate over acquiring EBV infection
through transfusion-related sources. Some reports have
shown that EBV can be transmitted and induce infectious
mononucleosis if the donors were viremic for EBV at the
time of donation [5]. Symptoms would develop 5–7 weeks
after blood product transfusion. However in a study by Wag-
neretal.,theeﬀectsoftransfusing 15EBV-seropositiveblood
products in 15 EBV-seronegative patients were assessed,
and the results did not indicate EBV transmission [6].
Nevertheless, it is prudent to avoid the risks of transfusing
bloodproductsthatareknowntobecontaminatedwithEBV.
Due to its rare occurrence, it is challenging to make
deﬁnitive therapeutic recommendations for PTLD. Treat-
ment strategies are primarily based on anecdotal reports.
Comparative data to evaluate treatment options are cur-
rently lacking. The cornerstone of therapy is the reductionJournal of Transplantation 3
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Figure 2: Lymph node architecture has been subtotally replaced by a diﬀuse proliferation of small, medium, and large lymphoid cells.
(a)positiveLMP-1stain,(b) positive CD-20 antibody stain.ImmunohistochemicalstainingwithKappa andLambda (candd,resp.) showed
many transformed cells and was positive for plasma cells.
Figure3:CTscanofchestposttreatment showedmediastinalnodes
decreasing in size.
or complete withdrawal of immunosuppressive therapy for
enhancement of cellular immunity. This allows the normal-
ization of the T-cell immunity and reduces proliferation of
the transformed B cells. Of course, this is in concert with
balancing the risk of allograft rejection. In the management
of EBV-associated PTLD, the control of the EBV infection
may or may not play a pivotal role, but antiviral therapy
has been advocated by some centers [7]. European best
practice guidelines recommend the use of antivirals for at
least 1 month after the diagnosis of PTLD [8]. Acyclovir,
valganciclovir, or ganciclovir are ﬁrst-line therapeutic rec-
ommendations. When monitoring the EBV PCR values in
association with PTLD, the DNA levels generally fall within
2 weeks and become undetectable by reducing immunosup-
pression and initiating antiviral therapy [7, 9]. Patients have
been reported to have peak plasma EBV DNA PCR levels
of 663,000copies/mL [9]. In our case, it was clearly evident
that clinical response of PTLD was eﬀectively attained with
reduction in the immunosuppression regimen, but DNA
copiesofEBVbyPCRwerepersistentlydetectedathighlevels
weeks after.
Controlling EBV infection is generally successful with
nucleoside analogues, butEBV viral loads can be exceedingly
high despite the continuous administration of intravenous
ganciclovir in patients with PTLD. The mechanism of
action of nucleoside analogues, such as ganciclovir is the
inhibition of viral DNA polymerase and aﬀecting cells
that undergo lytic cycle. Their use in EBV-infected PTLD
cases is of limited value because as many as 90% of
EBV-infected PTLD lesions are transformed cells that do4 Journal of Transplantation
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Figure 4: Graph indicating the EBV DNA PCR trends while on
intravenous ganciclovir and foscarnet.
not undergo lytic replication. Foscarnet is distinct from
the nucleoside analogues such that it does not require
viral enzyme activation. Therefore, foscarnet was a logical
alternative based on clinical assessment. Its use has been
reported in another patient with EBV-associated PTLD who
received a heart and kidney transplant (10). That patient had
asuccessful and persistent 10-month remission ofthe disease
with reduction in the level of immunosuppression and
a 4-week foscarnet therapy. Similar to our case, anti-CD 20
monoclonal antibodies orchemotherapeuticagents were not
required for the resolution of the PTLD and EBV infection.
4.Conclusion
EBV-associated PTLD typically occurs in the setting of
profound immunosuppression. The resulting impairment of
EBV-speciﬁc cytotoxic T lymphocytes (CTLs), donor and
recipientseropositivity,andHLA-A3expression andprimary
transmission are the primary risk factors for developing
PTLD. It is challenging to standardize a comprehensive
treatment strategy due to PTLD rare occurrence. A rapid
reduction or complete withdrawal of immunosuppression is
the hallmark of therapy. Antiviral therapy to control EBV
infections is controversial, but still advocated. Nucleoside
analogues such as acyclovir, valganciclovir, or ganciclovir
are of limited value in EBV-associated PTLD due to the
proliferation of the cells remaining in latent form and
requiring viral enzyme activation.
Generally, EBV PCR values are undetectable with clinical
remission ofPTLD. Our patient showed signiﬁcant improve-
ment of PTLD features by merely decreasing immunosup-
pression levels. However, the EBV PCR values continued
to escalate while receiving nucleoside analogue against
persistent EBV infection following clinical remission of
lymphadenopathy. The use of foscarnet in combination
with immunoglobulins resulted in successful reduction in
EBV PCR values. This is only the second case reported of
a persistent and successful remission of EBV infection and
PTLD. Further analysis is warranted to assess foscarnet’s role
as a ﬁrst-line agent for the control of EBV associated with
PTLD.
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